Affiliation:
1. Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing 100850, China
Abstract
Alzheimer’s disease (AD) is the most frequent cause of cognitive impairment in middle-aged and older populations. There is a lack of drugs that demonstrate significant efficacy in AD, so the study of the pathogenesis of AD is of great importance. More efficacious interventions are needed, as reflected by our population’s fast aging. Synaptic plasticity is the capacity of neurons to adjust their connections, and it is strongly tied to learning and memory, cognitive function, and brain injury recovery. Changes in synaptic strength, such as long-term potentiation (LTP) or inhibition (LTD), are thought to represent the biological foundation of the early stages of learning and memory. The results of numerous studies confirm that neurotransmitters and their receptors play an important role in the regulation of synaptic plasticity. However, so far, there is no definite correlation between the function of neurotransmitters in aberrant neural oscillation and AD-related cognitive impairment. We summarized the AD process to understand the impact of neurotransmitters in the progression and pathogenesis of AD, including the current status of neurotransmitter target drugs, and the latest evidence of neurotransmitters’ function and changes in the AD process.
Funder
National Natural Science Foundation of China
Logistics Research Program
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference100 articles.
1. Therapeutics of Neurotransmitters in Alzheimer’s Disease;Kandimalla;J. Alzheimers Dis.,2017
2. Arumugam, Dong-Gyu Jo, Physiology and pharmacology of amyloid precursor protein;Cho;Pharmacol. Ther.,2022
3. The link between C-reactive protein and Alzheimer’s disease among mexican Americans;Johnson;J. Alzheimer’s Dis. Jad,2012
4. A vicious cycle of β amyloid-dependent neuronal hyperactivation;Zott;Science,2019
5. Tau immunotherapies for Alzheimer’s disease;Hoskin;Expert Opin. Investig. Drugs,2019
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献